Novo Nordisk says FDA rejects insulin drugs
NEW YORK (AP) — Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.
The Danish drugmaker says it received a "complete response letter" from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.
In November, panel of federal health advisers recommended that the government approve degludec. The FDA is not required to follow the group's advice, but it often does.
Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.
Diabetics either do not produce enough of the hormone insulin or do not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood.
News Photo Galleriesview all
- 79546Oklahoma tornadoes: 'It took it all'
- 30543Oklahoma Severe Storm Updates
- 28179Oklahoma State football: Limiting Wes Lunt's transfer options makes Mike Gundy look bad
- 26729Oklahoma weather: Crews work to clear storm damage in Oklahoma City as the state braces for severe weather Sunday.
- 7711Bounty hunters look for bail jumpers, fugitives on the streets of Oklahoma City
- 7142Oklahoma City Thunder: What could Serge Ibaka learn from Hakeem Olajuwon?
- 7088Oklahoma tornadoes: Several homes damaged by tornado, but no injuries in Edmond